CA3297601A1 - Methods and compositions for treating ctnnb1-associated disorders - Google Patents

Methods and compositions for treating ctnnb1-associated disorders

Info

Publication number
CA3297601A1
CA3297601A1 CA3297601A CA3297601A CA3297601A1 CA 3297601 A1 CA3297601 A1 CA 3297601A1 CA 3297601 A CA3297601 A CA 3297601A CA 3297601 A CA3297601 A CA 3297601A CA 3297601 A1 CA3297601 A1 CA 3297601A1
Authority
CA
Canada
Prior art keywords
ctnnb1
compositions
treating
methods
associated disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3297601A
Other languages
French (fr)
Inventor
Gloria Lau
Wendy Broom
Akin Akinc
Arthur DeCillis
Martin A. Maier
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of CA3297601A1 publication Critical patent/CA3297601A1/en
Pending legal-status Critical Current

Links

CA3297601A 2023-08-04 2024-07-25 Methods and compositions for treating ctnnb1-associated disorders Pending CA3297601A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63/530,716 2023-08-04
US63/662,507 2024-06-21

Publications (1)

Publication Number Publication Date
CA3297601A1 true CA3297601A1 (en) 2025-02-13

Family

ID=

Similar Documents

Publication Publication Date Title
EP4352079A4 (en) Compositions and methods for treating neurofibromatic disorders
EP4096675A4 (en) Compositions and methods for treating long covid
EP4340836A4 (en) Methods and compositions for treating neurological conditions
EP4341382A4 (en) Compositions and methods for treating disease
EP4175978A4 (en) Compositions and methods for treating crp-mediated diseases
EP4216988A4 (en) Compositions and methods for treating and/or preventing autoimmune disorders
CA3261972A1 (en) Compositions and methods for treating metabolic disorders
CA3297601A1 (en) Methods and compositions for treating ctnnb1-associated disorders
HK40131011A (en) Methods and compositions for treating hsd-1-mediated disorders
CA3278656A1 (en) Methods and compositions for treating hsd-1-mediated disorders
AU2022903123A0 (en) Compositions and methods for treating disorders
HK40110376A (en) Compositions and methods for treating neurofibromatic disorders
CA3285901A1 (en) Microbiota compositions and methods for treating disorders
AU2023900704A0 (en) Microbiota Compositions and Methods for Treating Disorders
AU2024363527A1 (en) Compositions and methods for treating gastrointestinal-related diseases and disorders
CA3308877A1 (en) Compositions and methods for treating gastrointestinal-related diseases and disorders
CA3305935A1 (en) Compositions and methods for treating pain disorders
AU2024374758A1 (en) Compositions and methods for treating skin disorders
CA3305929A1 (en) Methods and compositions for treating cardio-pulmonary disorders
AU2022901710A0 (en) Compositions and methods for treating neurological disorders
AU2022900640A0 (en) Compositions and methods for treating neurological disorders
CA3281552A1 (en) Compositions and methods for treating hyperprocalcitonemia
CA3278586A1 (en) Compositions and methods for treating alpha-synucleinopathies
AU2022900643A0 (en) Compositions and Methods for Treating Non-Neurological Disorders
IL326321A (en) Methods and compositions for treating ctnnb1-associated disorders